The Risks of Trying GLP-1 Microdosing Without Medical Guidance GLP-1 microdosing may be discussed as a lower-intensity option, but trying it without clinical oversight can increase risk
Ozempic or others, consider their active ingredients, costs, and recommended uses
Policy changes like the Inflation Reduction Acts $2,000 out-of-pocket (OOP) cap for Medicare Part D beneficiaries may offer some relief, as patients who reach the cap pay $0 thereafter, but they also risk prompting payers to tighten coverage for high-cost drugs, especially those indicated for obesity
GLP-1 companion apps are a win-win for pharma, health plans, behavior change app publishers and patients
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes